The Conundrum of the PFOA Human Half-life


A coalition of interested parties is being formed to explore and possibly resolve the conundrum in human 1/2 life for perfluorooctanote (PFOA), which is reflected in differences in safe doses world-wide of 750-fold (Mikkonen et al., 2020).  A recent paper has been submitted that addresses this conundrum in part (Dourson and Gadagbui, 2021).  This collaboration started in April of 2021 with nominations to an advisory committee* who will then lead the coalition through a series of virtual and possibly face-to-face meetings, with conclusions expected later this year.   Toxicology Excellence for Risk Assessment ( has been designated as the nonprofit organization to support this coalition by the ARA Steering Committee (  Because TERA is a 501c3 nonprofit organization, all donations to this effort are tax deductible. 


For interest in joining the coalition, please contact Michael Dourson at


For a reading list of relevant references please click here.


*Advisory Committee:  Nominations to this advisory committee are welcome by the end of April 2021.  Selection of members for this committee will be made during first week of May 2021 by the ARA Steering Committee.  


Supporting References:
Dourson, Michael and Bernard Gadagbui. 2021.  The Dilemma of Perfluorooctanoate (PFOA) Human Half-life.  Toxicology Excellence for Risk Assessment (TERA).  Paper submitted to Regulatory Toxicology and Pharmacology.  March 31.


Dourson, Michael, Bernard Gadagbui, Chijioke Onyema, Patricia M. McGinnis, Raymond G. York.  2019.  Data derived Extrapolation Factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA).  Regulatory Toxicology and Pharmacology. 108: 104446. [Paper of the year, Society of Toxicology, Regulatory and Safety Evaluation Specialty Section]


Mikkonen, Antti T., Jennifer Martin, Michael L. Dourson, Andrea Hinwood, Mark S. Johnson.  2020.  Suggestions for Improving the Characterisation of Risk from Exposures to Per and Polyfluorinated Alkyl Substances (PFAS). Environmental Toxicology and Chemistry: 01:1-16.


*Advisory Committee:

  • Harvey Clewell, Ramboll 
  • Tony Cox, Cox and Associates
  • Michael Dourson, Toxicology Excellence for Risk Assessment
  • Shannon Ethridge, International Association of Plumbing and Mechanical Officials
  • Ali Hamade, Oregon Health Authority
  • Ravi Naidu, Cooperative Research Centre for Contamination Assessment and Remediation of the Environment
  • Nitin Verma, Chitkara University



Project Contact:
Dr. Michael Doursoni

Interested Partners:



Hull and Associates